VeriMomtasmannia lanceolata leaf extract hamilelikte güvenli mi?
No harmonised CLP reproductive classification (ECHA Annex VI) or SCCS/CIR safety assessment was identified for Tasmannia lanceolata leaf extract. A search of peer‑reviewed literature (PubMed) yields no controlled reproductive or developmental toxicity studies implicating this botanical; dominant constituents (e.g., polygodial) are described for irritancy/antimicrobial activity but not for teratogenicity. Therefore default hazard/mechanism scores are 0 and expected exposure from topical cosmetic use is low (e=0). Sources: ECHA Annex VI (no harmonised CLP entry), PubMed, CosIng, PubChem.
Pregnancy-safe products containing tasmannia lanceolata leaf extract
Related ingredients
Frequently asked questions
- tasmannia lanceolata leaf extract hamilelikte güvenli mi?
- No harmonised CLP reproductive classification (ECHA Annex VI) or SCCS/CIR safety assessment was identified for Tasmannia lanceolata leaf extract. A search of peer‑reviewed literature (PubMed) yields no controlled reproductive or developmental toxicity studies implicating this botanical; dominant constituents (e.g., polygodial) are described for irritancy/antimicrobial activity but not for teratogenicity. Therefore default hazard/mechanism scores are 0 and expected exposure from topical cosmetic use is low (e=0). Sources: ECHA Annex VI (no harmonised CLP entry), PubMed, CosIng, PubChem.
- tasmannia lanceolata leaf extract emzirirken güvenli mi?
- No evidence in regulatory sources or peer‑reviewed literature of lactation-specific risks or transfer via breast milk for this ingredient. No harmonised classifications or CIR/SCCS opinions raising reproductive/lactational concerns. Topical cosmetic exposure is expected to be low for mother (e=0). Sources: PubMed, CosIng, ECHA Annex VI.
- tasmannia lanceolata leaf extract bebek cildi için güvenli mi?
- No infant‑specific reproductive or developmental toxicity data found. Hazard and mechanism remain 0 due to absence of evidence of reproductive/ED effects. Exposure score increased by +1 (e=1) for 0–3‑year‑old skin because infant barrier immaturity increases potential percutaneous uptake relative to adults and because the ingredient is not an inherently non‑absorbable mineral; however, no data quantify neonatal absorption. Note: known concerns for this extract are primarily topical irritancy/allergenicity (from compositional constituents such as polygodial) rather than reproductive toxicity. Sources: PubMed, CosIng, EWG.
- VeriMom tasmannia lanceolata leaf extract nasıl puanlıyor?
- VeriMom tasmannia lanceolata leaf extract'yi EU CosIng, ECHA sınıflandırmaları ve PubMed çalışmalarına göre 100/100 (bilinen risk yok) olarak puanlar.
- Hamilelikte tasmannia lanceolata leaf extract yerine neler kullanılabilir?
- Benzer işlevli ve bilinen riski olmayan alternatifleri içeren listemize bakın.
Her etiketi 2 saniyede kontrol et
VeriMom'u ücretsiz indirin — herhangi bir ürünü tarayın ve hamilelik güvenlik puanını anında görün.
Tıbbi Sorumluluk Reddi
Bu bilgiler yalnızca eğitim amaçlıdır ve tıbbi tavsiye niteliği taşımaz. Güvenlik puanları kamuya açık verilere dayanmaktadır ve tüm riskleri yansıtmayabilir. Hamilelik veya emzirme döneminde herhangi bir ürünü kullanmadan önce her zaman sağlık uzmanınıza danışın.